Atrovent HFA Approval Breathes New Life Into Boehringer Ingelheim's Brand
This article was originally published in The Pink Sheet Daily
Executive Summary
The CFC-free version of the bronchodilator will receive three years of labeling exclusivity. FDA action to move ozone-depleting products off the market could remove BI's generic Atrovent competition.